Initiation of phase 1 trial of remyelinating antibody in people with MS
Mayo Clinic and Acorda Therapeutics, Inc. announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures....... Read More -http://www.ms-uk.org/index.cfm/myelin
Initiation of phase 1 trial of remyelinating antibody
Initiation of phase 1 trial of remyelinating antibody
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2030 Views
-
Last post by NHE
-
- 0 Replies
- 10620 Views
-
Last post by NHE
-
- 7 Replies
- 1566 Views
-
Last post by Jaded
-
- 0 Replies
- 1478 Views
-
Last post by frodo
-
- 0 Replies
- 1101 Views
-
Last post by frodo
-
- 0 Replies
- 1455 Views
-
Last post by NHE
-
- 2 Replies
- 3849 Views
-
Last post by DIM
-
- 1 Replies
- 2700 Views
-
Last post by Tif
-
- 0 Replies
- 2191 Views
-
Last post by NHE